Guangzhou University of Chinese Medicine, Guangzhou, China; Sun Yat-sen University, Guangzhou, China.
Guangzhou University of Chinese Medicine, Guangzhou, China; Sun Yat-sen University, Guangzhou, China; The First Affiliated Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
J Ethnopharmacol. 2023 Jan 30;301:115774. doi: 10.1016/j.jep.2022.115774. Epub 2022 Oct 4.
The effectiveness and safety of huaier granules in reducing recurrence after curative resection of HCC have been confirmed, but it is unclear whether huaier granules can significantly prolong overall survival.
To demonstrate the effectiveness of huaier granule for HCC after curative resection over a 5-year follow-up.
A total of 1265 HCC patients who underwent curative resection from January 2008 to January 2020 were enrolled, 1111 patients were finally enrolled according to the exclusion criteria, and the oncology outcome of Huaier granule was analyzed by propensity score matching method (PSM).
Before propensity score matching, huaier granule resulted in better 5- year overall survival (61.49% vs 54.92%, p = 0.0099) and recurrence-free survival (45.64% vs 38.42%, p = 0.0042) for HCC patients. For solitary HCC ≤30 mm, huaier granule resulted in similar 5- year recurrence-free survival (54.55% vs 50.13%, p = 0.4403), but better 5- year overall survival (82.42% vs70.08%, p = 0.0189). Similar to overall patients, huaier granule resulted in better 5- year overall survival (54.77% vs 51.37%, p = 0.1530) and recurrence-free survival (42.61% vs 35.62%, p = 0.0082) for solitary HCC >30 mm. After propensity score matching, we did confirm that huaier granules can significantly prolong overall survival by more than 5 years, the exception was recurrence-free survival in the HCC <30 mm cohort.
槐耳颗粒在降低 HCC 根治性切除术后复发方面的有效性和安全性已得到证实，但槐耳颗粒是否能显著延长总生存期尚不清楚。
在 5 年随访期间，证明槐耳颗粒对 HCC 根治性切除术后的疗效。
共纳入 1265 例 2008 年 1 月至 2020 年 1 月期间接受根治性切除术的 HCC 患者，根据排除标准最终纳入 1111 例患者，采用倾向评分匹配法（PSM）分析槐耳颗粒的肿瘤学疗效。
在倾向评分匹配前，槐耳颗粒可使 HCC 患者的 5 年总生存率（61.49% vs 54.92%，p=0.0099）和无复发生存率（45.64% vs 38.42%，p=0.0042）更好。对于单发 HCC≤30mm，槐耳颗粒可使 5 年无复发生存率相似（54.55% vs 50.13%，p=0.4403），但总生存率更好（82.42% vs 70.08%，p=0.0189）。与总体患者相似，槐耳颗粒可使单发 HCC＞30mm 的患者的 5 年总生存率（54.77% vs 51.37%，p=0.1530）和无复发生存率（42.61% vs 35.62%，p=0.0082）更好。经倾向评分匹配后，我们确实证实槐耳颗粒可使总生存期延长 5 年以上，但 HCC＜30mm 队列的无复发生存率除外。
